Amgen Inc. v. Sanofi (2022)
- Docket
- 21-757
- Decided
- 2022-01-01
- Public Good score
- 80 / 100
- Framers' Intent score
- 75 / 100
Summary
Question: <p>Do Amgen’s two patents satisfy the Patent Act’s enablement clause—that is, describing the invention with sufficient particularity that would enable a “skilled artisan” to “make and use” the claimed invention?</p> Conclusion: <p>Amgen’s two patent applications—purporting to cover all antibodies that bind and block the PCSK9 receptor involved in LDL cholesterol metabolism—fail to satisfy the Patent Act’s enablement clause. Justice Neil Gorsuch authored the unanimous opinion of the Court affirming the judgment below.</p> <p>It is well established that the enablement requirement means that if a patent claims an entire class of process, machines, manufactures, or compositions of matter, its specification must enable a person skilled in the art to make and use the entire class. While the specification may call for a reasonable amount of experimentation to make and use a claimed invention, it must not be too broad. Amgen’s specification fails to enable all that it has claimed, even allowing for a reasonable degree of experimentation. It described 26 antibodies by their amino acid sequences, but it claims to monopolize an entire class of antibodies not described. Thus, its claim is too broad.</p>
Case Brief
Facts
Amgen held two patents claiming all antibodies that bind and block the PCSK9 receptor, a target for LDL cholesterol reduction. The patents described only 26 specific antibodies via their amino acid sequences but sought to monopolize an entire class of such antibodies. Amgen argued that describing 26 exemplars satisfied the enablement requirement for the broader class.
Procedural History
The Federal Circuit affirmed the district court's grant of summary judgment that Amgen's patents were invalid for failing to satisfy the enablement requirement. Amgen appealed to the Supreme Court, which granted certiorari to resolve a circuit split on patent enablement standards.
Issue
Whether Amgen's patent claims covering all antibodies binding to the PCSK9 receptor satisfy the Patent Act's enablement clause by enabling a skilled artisan to make and use the entire claimed class without undue experimentation.
Holding
Yes, Amgen's patents fail to satisfy the enablement requirement because they claim an entire class of antibodies without providing sufficient disclosure to enable a skilled artisan to make and use all such antibodies.
Rule
A patent claiming an entire class of inventions must enable the full scope of the claimed class. While a reasonable degree of experimentation may be permitted, the specification must not be too broad, requiring detailed disclosure of the claimed class's critical features or enabling a practitioner to navigate the class without undue burden.
Reasoning
The Court held that Amgen's specification described only 26 antibodies but claimed all antibodies binding to PCSK9, creating an unenforceably broad claim. The Court rejected Amgen's argument that describing a few examples sufficed, emphasizing that the enablement requirement prevents patentees from securing monopolies over undiscovered inventions. The specification failed to enable the full scope of the claim even with reasonable experimentation, as it did not provide a workable method to identify or produce the claimed antibodies.
Significance
This decision reinforces the Patent Act's enablement requirement, setting a clear standard that patent claims must be supported by sufficient disclosure to enable the entire claimed class, not just a subset. It prevents patent thickets in biotechnology by mandating meaningful guidance for practitioners, thereby promoting genuine innovation over speculative monopolies.
Public Good Analysis
GPT: The ruling prevents overly broad patent monopolies that could stifle competition in life-saving cholesterol treatments, ensuring generic drug development and lower healthcare costs. This directly advances public health by promoting access to affordable therapeutics for cardiovascular disease management. | Claude: This decision clarifies the boundaries of patent law, preventing overly broad patents that could stifle innovation in pharmaceutical development. By requiring a reasonable connection between the described examples and the full scope of claims, it promotes access to potentially life-saving treatments by limiting monopolies on future discoveries. The ruling protects against 'patent thickets' and encourages genuine advancements rather than simply claiming extensive rights over general scientific principles.
Framers' Intent Analysis
GPT: The Court's interpretation aligns with the Constitution's Patent Clause (Art. I, § 8), which mandates patents only for 'promoting the Progress of Science.' This requires specific disclosure to enable industry advancement—consistent with James Madison's original framing and early cases like Beecher v. Loom (1823) establishing enablement as essential to prevent 'futile monopolies.' | Claude: The Patent Clause (Article I, Section 8, Clause 8) aimed to ‘promote the Progress of Science and useful Arts.’ While the framers certainly intended to incentivize innovation through patent protection, James Madison’s notes suggest concerns about monopolies and ensuring advancements were tangibly disclosed. This ruling aligns with that intent by preventing patents detached from concrete examples—effectively requiring inventors to demonstrate *how* their invention works, not simply describe a broad concept which echoes the spirit of practical application valued during the founding era.